Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 5% – Time to Sell?

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) dropped 5% on Thursday . The stock traded as low as $3.57 and last traded at $3.5450. Approximately 366,023 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 2,568,063 shares. The stock had previously closed at $3.73.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 9th. Zacks Research cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Wells Fargo & Company upped their target price on Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $5.34.

Ironwood Pharmaceuticals Stock Performance

The company’s 50 day moving average price is $2.21 and its 200-day moving average price is $1.35. The stock has a market cap of $578.65 million, a P/E ratio of 22.30 and a beta of 0.18.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.15. The business had revenue of $122.06 million during the quarter, compared to the consensus estimate of $74.22 million. Ironwood Pharmaceuticals had a net margin of 8.70% and a negative return on equity of 15.17%. On average, analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Large investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC lifted its position in shares of Ironwood Pharmaceuticals by 21.4% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 3,406 shares during the last quarter. McAdam LLC purchased a new stake in Ironwood Pharmaceuticals during the first quarter valued at about $40,000. Vise Technologies Inc. bought a new position in Ironwood Pharmaceuticals during the third quarter worth about $39,000. BNP Paribas Financial Markets increased its stake in shares of Ironwood Pharmaceuticals by 83.2% in the third quarter. BNP Paribas Financial Markets now owns 34,331 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 15,594 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd bought a new stake in shares of Ironwood Pharmaceuticals in the second quarter valued at approximately $25,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.